Compare FuelCell Energy Inc (FCEL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Revvity Inc — how do they compare? FuelCell Energy Inc trades at $17.64 (market cap $1.47B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: Revvity Inc is far larger — about 11.7× FuelCell Energy Inc's market cap, and Revvity Inc pays a 0.18% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Revvity Inc for 12 Days on average.
| FCEL | RVTY | |
|---|---|---|
Market Cap | $1.47B | $17.14B |
Volume | 12,559,948 | 2,226,396 |
Sector | Industrials | Health |
52-Week High | $36.01 | $157.36 |
52-Week Low | $6.00 | $82.26 |
Typical Hold Time | 48 Days | 12 Days |
Enterprise Value | $1.05B | $19.46B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.245, down 16.49% over 24 hours, reflecting recent volatility amid a securities class action. The stock shows a bullish technical signal with support near $17 and resistance at $19. Fundamentally, the company reported revenue of $158.16 million for 2025 but posted a net loss of $187.90 million, with negative profit margins persisting. Cash flow improved in 2025 with net cash flow of $132.91 million, though operational cash flow remains negative.
The outlook is cautious; while analyst consensus suggests a $21.57 price target with 40% buy ratings, ongoing legal challenges and consistent losses pose significant risks. Investment opportunity hinges on execution turnaround and market adoption of hydrogen energy, but high volatility and financial instability warrant careful consideration.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
